1. Home
  2. RCUS vs IGR Comparison

RCUS vs IGR Comparison

Compare RCUS & IGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCUS
  • IGR
  • Stock Information
  • Founded
  • RCUS 2015
  • IGR 2004
  • Country
  • RCUS United States
  • IGR United States
  • Employees
  • RCUS N/A
  • IGR N/A
  • Industry
  • RCUS Biotechnology: Pharmaceutical Preparations
  • IGR Finance Companies
  • Sector
  • RCUS Health Care
  • IGR Finance
  • Exchange
  • RCUS Nasdaq
  • IGR Nasdaq
  • Market Cap
  • RCUS 906.4M
  • IGR 752.8M
  • IPO Year
  • RCUS 2018
  • IGR N/A
  • Fundamental
  • Price
  • RCUS $9.60
  • IGR $5.05
  • Analyst Decision
  • RCUS Buy
  • IGR
  • Analyst Count
  • RCUS 8
  • IGR 0
  • Target Price
  • RCUS $20.86
  • IGR N/A
  • AVG Volume (30 Days)
  • RCUS 891.1K
  • IGR 747.7K
  • Earning Date
  • RCUS 08-07-2025
  • IGR 01-01-0001
  • Dividend Yield
  • RCUS N/A
  • IGR 13.93%
  • EPS Growth
  • RCUS N/A
  • IGR N/A
  • EPS
  • RCUS N/A
  • IGR N/A
  • Revenue
  • RCUS $141,000,000.00
  • IGR N/A
  • Revenue This Year
  • RCUS N/A
  • IGR N/A
  • Revenue Next Year
  • RCUS $28.73
  • IGR N/A
  • P/E Ratio
  • RCUS N/A
  • IGR N/A
  • Revenue Growth
  • RCUS N/A
  • IGR N/A
  • 52 Week Low
  • RCUS $6.50
  • IGR $3.88
  • 52 Week High
  • RCUS $18.98
  • IGR $5.70
  • Technical
  • Relative Strength Index (RSI)
  • RCUS 53.46
  • IGR 35.89
  • Support Level
  • RCUS $9.14
  • IGR $4.94
  • Resistance Level
  • RCUS $9.62
  • IGR $5.37
  • Average True Range (ATR)
  • RCUS 0.44
  • IGR 0.08
  • MACD
  • RCUS 0.04
  • IGR -0.04
  • Stochastic Oscillator
  • RCUS 62.85
  • IGR 9.52

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

About IGR CBRE Global Real Estate Income Fund of Beneficial Interest

CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.

Share on Social Networks: